Medical Device Definition under EU MDR Article 2(1) and Annex XVI

1. Key takeaways

The definition of a medical device in the European Union is set out in Article 2(1) of the MDR: any instrument, apparatus, appliance, software, implant, reagent, material or other article intended by the manufacturer to be used, alone or in combination, for humans for a specific medical purpose, and whose principal intended action is not achieved by pharmacological, immunological or metabolic means in or on the human body, although those means may assist its action. In addition, Annex XVI brings a group of products without an intended medical purpose within the scope of the MDR. The qualification decision therefore has two branches: the medical purpose route under Article 2(1), and the Annex XVI route for listed aesthetic and other non-medical product groups, each with its own downstream consequences for classification, assessment and evidence.

2. Legal basis

3. Expert insights

Insight 1: The principal intended action in the definition is the watershed of the qualification decision.

Both the official questions-and-answers of the European Commission and the summaries on EUR-Lex stress the same point: the principal intended action of a medical device is not achieved by pharmacological, immunological or metabolic means, although such means may assist its action. For a dressing containing an antimicrobial substance, or a catheter with a heparin coating, the analysis of the mechanism of action directly decides whether the product falls under the MDR or under the medicinal products framework. Borderline products are handled by the European Medicines Agency (EMA) together with the competent authorities through the established mechanisms. If the qualification decision is wrong, everything downstream must be redone: the classification, the assessment route and the clinical evidence are all built on that first conclusion, so the cost of an error grows with every stage it survives.

Insight 2: Annex XVI pulls aesthetic products into regulation, with common specifications attached.

Annex XVI of the MDR lists groups of products without an intended medical purpose, including certain active products. Through Implementing Regulation (EU) 2022/2346, amended by (EU) 2023/1194, the European Commission has adopted common specifications for such products, and through Implementing Regulation (EU) 2022/2347 it has completed the reclassification of the active product groups. This means that the argument that a product is not a medical device but merely a cosmetic or consumer product no longer works in the EU for the product groups listed in Annex XVI: those products must also undergo conformity assessment. Companies marketing such products should treat the Annex XVI route as a real regulatory project with its own documentation, evidence and assessment obligations, not as a formality.

Insight 3: Software is expressly within the scope of the definition.

Article 2(1) includes software in its enumeration of articles. Standalone software no longer takes its qualification from attached hardware; it is judged on its own intended purpose and is classified under Rule 11 of Annex VIII. This changed the practice under the previous directives, where standalone software was often handled as a low-risk product. For software manufacturers, the qualification file is now the single most important early document: it must state the intended purpose precisely, identify the decisions the software informs, and trace the path through the qualification and classification logic, because the classification that follows determines whether a notified body is involved at all.

Insight 4: In vitro diagnostic devices do not fall under the MDR.

In vitro diagnostic medical devices are governed by a separate regulation, Regulation (EU) 2017/746 (IVDR), applicable since 2022-05-26. The first step of every qualification decision is therefore to distinguish between four routes: device, IVD, medicinal product and Annex XVI product. The four routes differ in their legal sources, their classification rules and their transitional arrangements. A product that mixes features, for example an instrument with a companion diagnostic, may trigger more than one route, and the analysis must be documented before any development investment is committed to a particular framework.

4. Practical recommendations

1. At project initiation, issue a written qualification report citing Article 2(1) and working through the four routes: device, IVD, medicinal product and Annex XVI product.
2. For combination products (drug-device, device-Annex XVI), analyse the principal mechanism of action first and then choose the framework; never assume both parts can be handled as a device.
3. For Annex XVI products, check in parallel the applicable items of (EU) 2022/2346 and its amendment (EU) 2023/1194.
4. For software projects, issue a separate qualification document and follow the decision path of MDCG 2019-11.
5. Whenever a qualification conclusion changes, update the classification, the technical documentation and the UDI data at the same time, leaving no residual references to the earlier version.

5. Verification checklist

• □ A qualification report has been issued citing Article 2(1)
• □ The applicability of the IVDR (Regulation (EU) 2017/746) has been excluded or confirmed
• □ Whether the product falls within an Annex XVI product group has been confirmed
• □ Annex XVI products have been checked against (EU) 2022/2346 and (EU) 2023/1194
• □ Software products have completed qualification following MDCG 2019-11
• □ Combination products have completed the principal mechanism of action analysis

Regulatory information verified as of 29 October 2026.

About GRZAN. GRZAN guides manufacturers through the qualification decisions that determine the entire CE marking route in the European Union under Regulation (EU) 2017/745. We prepare written qualification reports for devices, software, combination products and Annex XVI product groups, align the analysis with the common specifications and reclassification acts adopted by the European Commission, and carry the conclusions forward into classification, technical documentation and notified body submissions. If you need a defensible, well-documented entry path into the EU MDR market, contact info@grzanglobal.com.